Skip to main content
Contact Us
Subscribe
E-Edition
55°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
2025 Calendar Photos
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Xencor Inc
(NQ:
XNCR
)
25.01
+0.91 (+3.78%)
Streaming Delayed Price
Updated: 4:00 PM EST, Nov 22, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Xencor Inc
< Previous
1
2
3
Next >
Xencor Reports Third Quarter 2024 Financial Results
November 06, 2024
From
Xencor, Inc.
Via
Business Wire
Xencor Doses First Subject in Phase 1/2 Study of XmAb®942 in Development for Patients with Inflammatory Bowel Disease
November 04, 2024
From
Xencor, Inc.
Via
Business Wire
Xencor Presents Preclinical Data on XmAb942, a High-Potency Extended Half-Life Anti-TL1A Antibody, to be Developed for Patients with Inflammatory Bowel Diseases
October 10, 2024
From
Xencor, Inc.
Via
Business Wire
Xencor Announces Upcoming Change to Board of Directors
October 04, 2024
From
Xencor, Inc.
Via
Business Wire
Xencor Announces Closing of Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
September 12, 2024
From
Xencor, Inc.
Via
Business Wire
Xencor Announces Pricing of $175 Million Public Offering of Common Stock
September 11, 2024
From
Xencor, Inc.
Via
Business Wire
Xencor Announces Proposed Public Offering of Common Stock
September 10, 2024
From
Xencor, Inc.
Via
Business Wire
Xencor Announces XmAb Drug Candidates in Autoimmune Disease with Near-Term Clinical Plans and Shares Clinical Progress in Early-Stage Oncology Programs
September 09, 2024
From
Xencor, Inc.
Via
Business Wire
Xencor to Host Research & Development Webcast and Conference Call on Monday, September 9, 2024
September 06, 2024
From
Xencor, Inc.
Via
Business Wire
Xencor Reports Second Quarter 2024 Financial Results
August 05, 2024
From
Xencor, Inc.
Via
Business Wire
Xencor Regains CD20 x CD3 Bispecific T-Cell Engager
June 13, 2024
From
Xencor, Inc.
Via
Business Wire
Xencor Reports First Quarter 2024 Financial Results
May 09, 2024
From
Xencor, Inc.
Via
Business Wire
Xencor Appoints Bart Cornelissen as Chief Financial Officer
April 09, 2024
From
Xencor, Inc.
Via
Business Wire
Xencor to Present at Upcoming Investor Conferences
February 28, 2024
From
Xencor, Inc.
Via
Business Wire
Xencor Reports Fourth Quarter and Full Year 2023 Financial Results
February 27, 2024
From
Xencor, Inc.
Via
Business Wire
Xencor to Host Webcast to Review Fourth Quarter and Full Year 2023 Financial Results and Provide Vudalimab Clinical Update
February 20, 2024
From
Xencor, Inc.
Via
Business Wire
Xencor to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 03, 2024
From
Xencor, Inc.
Via
Business Wire
Dane Leone Joins Xencor as Senior Vice President, Corporate Strategy
January 02, 2024
From
Xencor, Inc.
Via
Business Wire
Xencor Reports Third Quarter 2023 Financial Results
November 07, 2023
From
Xencor, Inc.
Via
Business Wire
Xencor Sells Portion of Royalties and Milestones from Ultomiris® and Monjuvi® to OMERS Life Sciences for $215 Million
November 07, 2023
From
Xencor, Inc.
Via
Business Wire
Xencor Presents Preclinical Data from Multiple XmAb® Research Programs at the SITC Annual Meeting
November 03, 2023
From
Xencor, Inc.
Via
Business Wire
Xencor to Host Third Quarter 2023 Financial Results Webcast and Conference Call on November 7, 2023
October 31, 2023
From
Xencor, Inc.
Via
Business Wire
Xencor Announces Planned Retirement of Chief Financial Officer John Kuch
October 26, 2023
From
Xencor, Inc.
Via
Business Wire
Xencor to Present Multiple Posters at the SITC Annual Meeting
September 27, 2023
From
Xencor, Inc.
Via
Business Wire
Xencor Appoints Barbara J. Klencke, M.D., to Board of Directors
September 19, 2023
From
Xencor, Inc.
Via
Business Wire
Xencor Reports Second Quarter 2023 Financial Results
August 03, 2023
From
Xencor, Inc.
Via
Business Wire
Xencor to Host Second Quarter 2023 Financial Results Webcast and Conference Call on August 3, 2023
July 27, 2023
From
Xencor, Inc.
Via
Business Wire
Xencor Presents Clinical Results from Phase 1a Study of XmAb®564 at the EULAR 2023 Congress
May 30, 2023
From
Xencor, Inc.
Via
Business Wire
Xencor Reports First Quarter 2023 Financial Results
May 08, 2023
From
Xencor, Inc.
Via
Business Wire
Xencor to Host First Quarter 2023 Financial Results Webcast and Conference Call on May 8, 2023
May 01, 2023
From
Xencor, Inc.
Via
Business Wire
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.